Skip to main content
Evidence Snapshot

5-hydroxytryptamine receptor 2B

CHEMBL323 SINGLE PROTEIN Rattus norvegicus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T23:51:41Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL323
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats 5-hydroxytryptamine receptor 2B as ChEMBL target CHEMBL323, mapped to UniProt P30994. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
5-hydroxytryptamine receptor 2B
SINGLE PROTEIN · Rattus norvegicus
As of 2026-09-13
ChEMBL target ID
CHEMBL323
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P30994
5-hydroxytryptamine receptor 2B
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why 5-hydroxytryptamine receptor 2B matters

As of 2026-09-13

5-hydroxytryptamine receptor 2B is reviewed as 5-hydroxytryptamine receptor 2B (UniProt P30994); the current evidence base includes 2 approved drugs, 253 compounds, and 37 assays, with lead potency reaching pChEMBL 10.1.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 2 approved drugs, 253 compounds, and 37 assays for this target. The dominant activity type is KD. CHEMBL5270056 is the current potency anchor at pChEMBL 10.1.

Use CHEMBL5270056 as the tractability anchor when discussing potency (pChEMBL 10.1).

Activity source · ChEMBL 36 via Core Engine
2 approved pChEMBL 10.1
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why 5-hydroxytryptamine receptor 2B matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P30994, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

253
Total Compounds
37
Total Assays
2
Approved Drugs
KI: 11.0, EC50: 19.0, KD: 142.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL5270056
 10.1 Ki —
No preferred name
CHEMBL5277645
 10.0 Ki —
No preferred name
CHEMBL5279881
 10.0 Ki —
No preferred name
CHEMBL5280131
 10.0 Ki —
No preferred name
CHEMBL5284094
 10.0 Ki —

Approved Drugs

Structure Compound First Approval
CLOZAPINE
CHEMBL42
 1989
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T23:51:41Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL323